1Haraldsson B, S(o)rensson J. Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier. News Physiol Sci, 2004, 19: 7-10.
2Singh R, Singh AK, Alavi N, et al. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol, 2003,14: 873-880.
3Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension, 2004, 43: 699-706.
4Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med, 1999,340:1321-1328.
5Mancia G, Grassi G, Giannattasio C, Gino seravalle sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension,1999,34[part 2]:724-728.
6Vattikuti R, Towler DA, Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol Endocrinol Metab, 2004,286: E686-E696.
7Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension, 2003, 41:1183-1190.
8Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest, 2002, 110:229-238.
9El-Atat FA, Stas SN, McFarlane SI, et al. The relationship between hyperinsulinemia,hypertension and progres renal disease. J Am Soc Nephrol, 2004,15: 2816 - 2827.
10Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol, 2004,15: 2792-2800.
